Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens
- 23 April 2003
- Vol. 32 (6) , 687-693
- https://doi.org/10.1016/s8756-3282(03)00091-7
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Ibandronate: A Comparison of Oral Daily Dosing Versus Intermittent Dosing in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2001
- Bisphosphonates for osteoporosisDrug and Therapeutics Bulletin, 2001
- Clinical Evaluation of the Elecsys β-CrossLaps Serum Assay, a New Assay for Degradation Products of Type I Collagen C-TelopeptidesClinical Chemistry, 2001
- Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosisBone, 2000
- Weekly administration of alendronate: Rationale and plan for clinical assessmentClinical Therapeutics, 2000
- Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral PropertiesJournal of Bone and Mineral Research, 1999
- IbandronateDrugs, 1999
- Three Monthly Intravenous Injections of Ibandronate in the Treatment of Postmenopausal OsteoporosisThe American Journal of Medicine, 1997
- Bisphosphonates: Preclinical Aspects and Use in OsteoporosisAnnals of Medicine, 1997
- The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding studyBone, 1996